Human papillomavirus (HPV) testing was introduced to compensate the poor sensitivity and specificity of the pap smear cytology often used as a diagnostic tool for borderline precancerous lesions. Digene Hybrid Capture Assay 2 (HCA-2) is the only approved test by the U.S. Food and Drug Administration (FDA) for evaluation and confirmation of the cytologically borderline suspected cases. 361 cervical specimens were collected for the high risk HPV analysis. Forty one cervical samples were positive. Age wise distribution showed highest prevalence in the 15-35 age groups which decreased in subsequent years. Present observations are in agreement with similar studies reported from other parts of the world including Southern India
Author(s): Narotam Sharma, Veena Sharma, Prem Raj Singh, R.S. Kushwaha, Satish Chandra Nautiyal,
Shivani Sailwal, Rajesh K Singh, Tariq Masood, Pankaj Mishra, R.K Singh
Abstract |
Full-Text |
PDF
Share this